Tag: asco 2021 highlights
Takeda’s Flagship Product Panitumumab (PAN)+mFOLFOX6 Versus bevacizumab (BEV) + mFOLFOX6
Takeda’s Flagship Product Panitumumab (PAN)+mFOLFOX6 Versus bevacizumab (BEV) + mFOLFOX6
0
0
0
8 Jul, 10:01 AM
Daiichi’s novel HER3 ADC has Shown To Have a Spark in HER3 NSCLC, post success in the HER3 Breast Cancer Trial
Daiichi’s novel HER3 ADC has Shown To Have a Spark in HER3 NSCLC, post success in the HER3 Breast Cancer Trial
0
0
0
30 Jun, 11:01 AM
Junshi’s domestic Toripalimab’s significant results in recurrent or metastatic HNSCC. CRL issued on Nasopharyngeal Carcinoma could prove to be a setback?
Junshi’s domestic Toripalimab’s significant results in recurrent or metastatic HNSCC. CRL issued on Nasopharyngeal Carcinoma could prove to be a setback?
0
0
0
29 Jun, 10:32 AM
